Protein Knockout Platform
- Detailed Technology Description
- Methods to eradicate proteins at mRNA and protein levelsKitscomprising engineered SCF ubiquitin ligase and corresponding siRNA
- Others
-
- Published US Patent Application US20130011920
- Zhou P, et al Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol Cell. 2000 Sep;6(3):751-6 (Pubmed 11030355)
- Zhang J, Zheng N, Zhou P. Exploring the functional complexity of cellular proteins by protein knockout. PNAS. 2003 Nov 25;100(24):14127-32. (Pubmed 14593203)
- Cong F e al. A protein knockdown strategy to study the function of beta-catenin in tumorigenesis. BMC Mol Biol. 2003 Sep 29;4:10. (Pubmed 14516475)
- Cohen JC et al Transient in utero knockout (TIUKO) of C-MYC affects late lung and intestinal development in the mouse. BMC Dev Biol. 2004 Apr 16;4:4. (Pubmed 15090077)
- Zhou P. Targeted protein degradation. Curr Opin Chem Biol. 2005 (Pubmed 15701453)
- *Abstract
-
Both RNAi and protein knockouttechnologies are able to reduce the steady state levels of cellular proteins ofinterest. Specifically, RNAi operates at the level of protein biosynthesis viadegrading specific mRNA or inhibiting its translation, protein removal from thecell, however, solely relies on the endogenous protein destruction machinery toremove the protein; whereas the proprietary protein knockout technologyfunctions at the post-translational level to accelerate the degradation of thedesired protein, but won't stop new protein synthesis. Our integrated RNAi andprotein knockout system therefore significantly improves the efficiency andkinetics of knocking down cellular proteins of interest, providing an excellentplatform for protein function interrogation. This integrated technology isespecially advantageous when manipulating proteins with a long half-life.
We have degradation vectorstargeting several key cellular proteins involved in cell growth control andtumorigensis, such as retinoblastoma protein, cytosol β–catenin, and p107 tumorsuppressor.
Potential Applications
- Kits for sale to the academic and commercial research markets
- Contract research, especially validating targets for pharma/biotech
- Possibly, development of drug candidates
- *Licensing
- Dan-Oscar Antsonda429@cornell.edu212-746-1297
- Country/Region
- USA

